Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiopulmonary revenue shifts, FDA trial updates, and executive stock sales all hide deep inside LivaNova’s SEC documents. For a medical-device maker whose fortunes depend on heart-lung machines and vagus-nerve stimulators, every line of a 10-K matters—and parsing it can consume days.
Stock Titan solves that problem. Our AI reads each LivaNova annual report 10-K simplified, every LivaNova quarterly earnings report 10-Q filing, and the continuous stream of LivaNova 8-K material events explained, extracting plain-English summaries and key metrics. Real-time alerts surface LivaNova insider trading Form 4 transactions so you can track LivaNova Form 4 insider transactions real-time without refreshing EDGAR. Need to evaluate pay packages? The platform highlights clauses inside the LivaNova proxy statement executive compensation.
Use cases include:
- Comparing segment margins across cardiopulmonary and neuromodulation with our LivaNova earnings report filing analysis.
- Monitoring clinical-trial disclosures to gauge pipeline timing.
- Flagging executive stock transactions Form 4 before earnings calls.
Whether you’re a portfolio manager assessing reimbursement risk or an analyst understanding LivaNova SEC documents with AI, every filing—10-K, 10-Q, 8-K, S-8, or SC 13G—arrives here within minutes of hitting EDGAR. Clean HTML, downloadable PDFs, and one-click AI highlights mean LivaNova SEC filings explained simply, so you spend time on decisions, not document hunts.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.
LivaNova PLC director reported share activity related to vested restricted stock units. On December 15, 2025, 2,355 ordinary shares were acquired at $0 upon the exercise of previously granted RSUs under the LivaNova PLC 2015 Incentive Award Plan. On the same date, 269 shares were disposed of at $63.06 to cover tax liabilities, leaving 2,086 ordinary shares beneficially owned directly after these transactions.
The RSUs were originally granted on December 15, 2024 with a one-year vesting schedule and were subject to forfeiture before vesting under the plan and award agreement.
LivaNova PLC senior vice president, chief legal officer and company secretary reported routine equity activity related to restricted stock units. On December 15, 2025, 2,254 RSUs vested and were settled in ordinary shares at an exercise price of $0, increasing her directly held stake. On the same date, 1,122 ordinary shares were withheld at $63.06 per share to cover tax obligations, leaving 6,798 ordinary shares held directly after the transactions. The underlying RSUs were originally granted on December 15, 2022, under the LivaNova PLC 2022 Incentive Award Plan with a four-year vesting schedule, and 2,253 RSUs remain beneficially owned following this vesting event.
LivaNova PLC director reports small share sale in Form 4 filing. A company director sold 250 ordinary shares of LivaNova PLC (LIVN) on 11/18/2025 at a price of $53.94 per share. After this transaction, the director beneficially owns 6,232 ordinary shares, held directly. This filing is a routine disclosure of insider activity required under securities regulations and does not by itself describe any change in the company’s operations or strategy.
LivaNova PLC reported stronger Q3 2025 results. Net revenue rose to $357.8 million from $318.1 million, with operating income of $54.0 million and net income of $26.8 million ($0.49 diluted). For the first nine months, the company posted a net loss of $273.4 million, primarily driven by the $363.8 million SNIA environmental liability expense booked earlier in the year.
Cash and cash equivalents were $646.1 million, aided by operating cash flow of $171.9 million year-to-date. LivaNova repaid $200 million on its Term Facilities in May, reducing long-term debt to $349.0 million. The company recorded a current liability of $394.6 million (€336.3 million) related to the SNIA matter, reflecting its best estimate including costs, fees, interest, and taxes.
On the cybersecurity incident disclosed in 2023, cumulative direct costs totaled $13.1 million through September 30, 2025, and insurance reimbursements received totaled $9.6 million. Ordinary shares outstanding were 54,605,527 as of October 29, 2025.
LivaNova PLC furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company will host a business update conference call and webcast on November 5, 2025, at 1 p.m. London time (8 a.m. Eastern Time), accessible via its events page.
The related press release is attached as Exhibit 99.1 and, under Item 2.02, is being furnished and not deemed filed under the Exchange Act.
LivaNova PLC (LIVN) director Donald Zurbay was granted 2,560 Restricted Stock Units (RSUs) on September 15, 2025. Each RSU converts to one ordinary share under the LivaNova PLC 2025 Director Incentive Award Plan. The grant carries vesting and forfeiture restrictions that are scheduled to lapse on June 15, 2026, subject to continued service and the award agreement. The reported RSUs have a $0 per-unit reported grant price on the Form 4 and are shown as directly beneficially owned following the award. The Form 4 was signed on behalf of the reporting person by an Attorney-in-Fact on September 17, 2025.
LivaNova PLC (LIVN) reporting person Franco Poletti had 643 restricted stock units (RSUs) vest and be settled into ordinary shares on September 15, 2025. Of those vested shares, 277 shares were withheld to satisfy tax withholding at an effective price shown as $55.43 per share, leaving 643 net shares credited from the RSU settlement in the transaction record. Following the reported transactions the form shows 8,576 shares beneficially owned by the reporting person, 8,299 shares after the withholding line, and 219 shares held indirectly by spouse. The RSUs were granted September 15, 2024 under the company’s 2022 Incentive Award Plan and vest in equal annual installments over four years, with the first vesting on September 15, 2025.
LivaNova PLC (LIVN) Form 3 filed for Donald Zurbay records that the reporting person is a Director and that the event date was 09/03/2025. The filing shows 0 ordinary shares beneficially owned directly. The form is signed by an attorney-in-fact and includes Exhibit 24 - Power of Attorney.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
